Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of HRS9531 Injection Formulations
NCT05893576Phase 1Completed
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- May 2023
- Primary completion
- Sep 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HRS9531 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Fujian Shengdi Pharmaceuticals. Primary endpoints: Area Under the Concentration versus time curve at Day 43, Maximum Concentration at Day 43 and 1 more. Started May 2023; status: completed.
02
Drugs
HRS9531
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05893576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05893576.